Characterisation of patients with postmenopausal osteoporosis in french primary healthcare

Drugs and Aging

Volumn 24, Issue 7, 2007, Pages 603-614

  Blotman, Francis ^a   Cortet, Bernard ^b   Hilliquin, Pascal ^c   Avouac, Bernard ^d   Allaert, François Andŕe ^e   Pouchain, Denis ^f   Gaudin, Anne Françoise ^g   Cotté, François Emery ^g   El Hasnaoui, Abdelkader ^g  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c CENTRE HOSPITALIER SUD FRANCILIEN   (France)

^d OFOS Observatoire Français Pour l'Ostéoporose   (France)

^e DIJON UNIVERSITY HOSPITAL   (France)

^f General Practice Department   (France)

^g GLAXOSMITHKLINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CHEMICAL ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; FRACTURE; FRANCE; GENERAL PRACTITIONER; HEALTH CARE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR; SCORING SYSTEM; SOCIAL ASPECT; VERTEBRATE;

ADULT; AGED; AGED, 80 AND OVER; AGING; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; FRANCE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; PHARMACOEPIDEMIOLOGY; PRIMARY HEALTH CARE; QUALITY OF LIFE; RISK FACTORS;

EID: 34547611600     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724070-00007     Document Type: Article

References (61)

1. National Institute of Health. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001 Feb 14; 285 (6): 785-95
2. Looker AC, Orwoll ES, Johnston Jr CC, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997 Nov; 12 (11): 1761-8
3. Tenenhouse A, Joseph L, Kreiger N, et al. Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 2000; 11 (10): 897-904
4. Dargent-Molina P, Piault S, Breart G. Identification of women at increased risk of osteoporosis: no need to use different screening tools at different ages. Maturitas 2006 Apr 20; 54 (1): 55-64
5. Ross PD, Davis JW, Epstein RS, et al. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991 Jun 1; 114 (11): 919-23
6. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures: the Study of Osteoporotic Fractures Research Group. Lancet 1993 Jan 9; 341 (8837): 72-5
7. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005 Mar; 16 Suppl. 2: S3-7
8. Grados F, Marcelli C, Dargent-Molina P, et al. Prevalence of vertebral fractures in French women older than 75 years from the EPIDOS study. Bone 2004 Feb; 34 (2): 362-7
9. The European Prospective Osteoporosis Study Group. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002 Apr; 17 (4): 716-24
10. Ismail AA, Pye SR, Cockerill WC, et al. Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 2002 Jul; 13 (7): 565-71
11. Baudoin C, Fardellone P, Potard V, et al. Fractures of the proximal femur in Picardy, France, in 1987. Osteoporos Int 1993 Jan; 3 (1): 43-9
12. Baudoin C, Fardellone P, Thelot B, et al. Hip fractures in France: the magnitude and perspective of the problem. Osteoporos Int 1996; 6 Suppl. 3: 1-10
13. Kanis JA, Johnell O, De Laet C, et al. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 2002 Jul; 17 (7): 1237-44
14. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999 Mar 13; 353 (9156): 878-82
15. Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993 May 1; 137 (9): 1001-5
16. Maravic M, Le Bihan C, Landais P, et al. Incidence and cost of osteoporotic fractures in France during 2001: a methodological approach by the national hospital database. Osteoporos Int 2005 Dec; 16 (12): 1475-80
17. Wehren LE, Magaziner J. Hip fracture: risk factors and outcomes. Curr Osteoporos Rep 2003 Sep; 1 (2): 78-85
18. Empana JP, Dargent-Molina P, Breart G. Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. J Am Geriatr Soc 2004 May; 52 (5): 685-90
19. Baudoin C, Fardellone P, Bean K, et al. Clinical outcomes and mortality after hip fracture: a 2-year follow-up study. Bone 1996 Mar; 18 (3 Suppl.): 149-57S
20. Hasserius R, Karlsson MK, Jonsson B, et al. Long-term morbidity and mortality after a clinically diagnosed vertebral fracture in the elderly: a 12- and 22-year follow-up of 257 patients. Calcif Tissue Int 2005 Apr; 76 (4): 235-42
21. Jalava T, Sarna S, Pylkkanen L, et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 2003 Jul; 1 8 (7): 1254-60
22. Kado DM, Duong T, Stone KL, et al. Incident vertebral fractures and mortality in older women: a prospective study. Osteoporos Int 2003 Jul; 14 (7): 589-94
23. Kanis JA, Oden A, Johnell O, et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004 Feb; 15 (2): 108-12
24. Melton III LJ. Excess mortality following vertebral fracture. J Am Geriatr Soc 2000 Mar; 48 (3): 338-9
25. Naves M, Diaz-Lopez JB, Gomez C, et al. The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population. Osteoporos Int 2003 Jul; 14 (6): 520-4
26. Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 2005 Jul; 17 (4): 462-6
27. Cranney A, Adachi JD. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf 2005; 28 (8): 721-30
28. Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006 Apr; 119 (4 Suppl. 1): S18-24
29. Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures: study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999 May; 14 (5): 821-8
30. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001 Jan 17; 285 (3): 320-3
31. Melton III LJ, Atkinson EJ, Cooper C, et al. Vertebral fractures predict subsequent fractures. Osteoporos Int 1999; 10 (3): 214-21
32. O'Neill TW, Felsenberg D, Varlow J, et al. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996 Jul; 11 (7): 1010-8
33. Delmas PD, van de Langerijt L, Watts NB, et al. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res 2005 Apr; 20 (4): 557-63
34. Girerd X, Hanon O, Anagnostopoulos K, et al. Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic [in French]. Presse Med 2001 Jun 16-23; 30 (21): 1044-8
35. Ware Jr J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996 Mar; 34 (3): 220-33
36. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006 Dec; 17 (12): 1726-33
37. Cumming RG. Nursing home residence and risk of hip fracture. Am J Epidemiol 1996 Jun 15; 143 (12): 1191-4
38. Brennan nee Saunders J, Johansen A, Butler J, et al. Place of residence and risk of fracture in older people: a population-based study of over 65-year-olds in Cardiff. Osteoporos Int 2003 Jul; 14 (6): 515-9
39. Norton R, Campbell AJ, Reid IR, et al. Residential status and risk of hip fracture. Age Ageing 1999 Mar; 28 (2): 135-9
40. Schwartz EN, Steinberg DM. Prescreening tools to determine who needs DXA. Curr Osteoporos Rep 2006 Dec; 4 (4): 148-52
41. Cadarette SM, McIsaac WJ, Hawker GA, et al. The validity of decision rules for selecting women with primary osteoporosis for bone mineral density testing. Osteoporos Int 2004 May; 15 (5): 361-6
42. Richy F, Ethgen O, Bruyere O, et al. Primary prevention of osteoporosis: mass screening scenario or prescreening with questionnaires? An economic perspective. J Bone Miner Res 2004 Dec; 19 (12): 1955-60
43. ANAES. Ostéodensitométrie [absorbimétrie osseuse] sur 2 sites par methode biphotonique 2006 [online]. Available from URL: http://www.has-sante.fr/portail/upload/docs/application/pdf/ osteodensitometrie_rapport.pdf [Accessed 2007 May 25]
44. Amamra N, Berr C, Clavel-Chapelon F, et al. Estimated number of women likely to benefit from bone mineral density measurement in France. Joint Bone Spine 2004 Sep; 71 (5): 409-18
45. Maurel F, Levy E, Le Pen C. Le côut hospitalier des fractures ostéoporotiques en France. J Econ Med 1998; 16 (2): 99-108
46. Albrand G, Munoz F, Sornay-Rendu E, et al. Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone 2003 Jan; 32 (1): 78-85
47. Chapurlat RD, Bauer DC, Nevitt M, et al. Incidence and risk factors for a second hip fracture in elderly women: the Study of Osteoporotic Fractures. Osteoporos Int 2003 Apr; 14 (2): 130-6
48. Bartl R, Gotte S, Hadji P, et al. [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment]. Dtsch Med Wochenschr 2006 Jun 2; 131 (22): 1257-62
49. McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004 Jul 15; 48 (3): 271-87
50. Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006; 17 (6): 914-21
51. Sambrook P. Compliance with treatment in osteoporosis patients: an ongoing problem. Aust Fam Physician 2006 Mar; 35 (3): 135-7
52. Allaert FA. Influence of the sociodemographic and clinical profile of dyslipidaemic patients on their compliance with dietary advice combined with cholesterol-lowering drug treatment (Nutrivast survey) [in French]. Ann Cardiol Angeiol (Paris) 2004 Sep; 53 (5): 279-89
53. More DR, Hagan LL. Factors affecting compliance with allergen immunotherapy at a military medical center. Ann Allergy Asthma Immunol 2002 Apr; 88 (4): 391-4
54. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005 Sep; 21 (9): 1453-60
55. Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 2006 Sep-Oct; 12 (5): 522-8
56. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005 Jul; 80 (7): 856-61
57. Cramer JA, Lynch NO, Gaudin AF, et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006 Oct; 28 (10): 1686-94
58. Cortet B, Benichou O. Adherence, persistence, concordance: do we provide optimal management to our patients with osteoporosis? Joint Bone Spine 2006 Oct; 73 (5): e1-7
59. Brenneman SK, Barrett-Connor E, Sajjan S, et al. Impact of recent fracture on health-related quality of life in postmenopausal women. J Bone Miner Res 2006 Jun; 21 (6): 809-16
60. Cockerill W, Lunt M, Silman AJ, et al. Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 2004 Feb; 15 (2): 113-9
61. van Schoor NM, Smit JH, Twisk JW, et al. Impact of vertebral deformities, osteoarthritis, and other chronic diseases on quality of life: a population-based study. Osteoporos Int 2005 Jul; 16 (7): 749-56